Biochemical characterization of a unique canine myeloid antigen.
In marrow transplantation, radioisotope-labeled monoclonal antibodies may provide a way to selectively deliver high doses of radiation to target tissues (marrow in the case of myeloid malignancies) without significant toxicity to other normal organs. This paper describes the production and characterization of a novel monoclonal antibody, DM5, that we have developed for use in an animal model of radiotherapy targeted to the marrow. DM5 recognizes three glycosylation variants, gp19,21,23DM5, of a polypeptide core that is expressed on canine cells of the myeloid lineage, but not on lymphoid cells. The antigen recognized by DM5 is not present on most progenitor cells as determined by CFU-GM assays of DM5 positive and negative cell populations.
Sandmaier
B M
BM
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Schuening
F G
FG
Bianco
J A
JA
Rosenman
S J
SJ
Bernstein
I
I
Goehle
S
S
Storb
R
R
Appelbaum
F R
FR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis* / Q000627:therapeutic use; D001853:Bone Marrow / Q000276:immunology*; D004285:Dogs / Q000276:immunology*; D015180:Electrophoresis, Gel, Two-Dimensional; D005434:Flow Cytometry; D007951:Leukemia, Myeloid / Q000532:radiotherapy; D010449:Peptide Mapping; D015531:Radioimmunoprecipitation Assay
D000911:Antibodies, Monoclonal